In a sign of national pride as well as the Netherlands, Crucell had become the largest biopharma firm by 2009. The case traces the development of the company from a University spin-off into a fully-incorporated business. Crucell has achieved success mainly in vaccine space, and started to draw the attention of much larger pharmaceutical companies.
These relationships may additionally challenge the liberty of Crucell, while there clearly was much allure to working with these firms. This dilemma is emphasized by the decision whether to associate with businesses that needed ownership of 10% to 20% of business advancement deals.
PUBLICATION DATE: February 13, 2015 PRODUCT #: 815085-HCB-ENG
This is just an excerpt. This case is about INNOVATION & ENTREPRENEURSHIP
Related Case Solutions & Analyses:
World Bank (A): Under Siege
InterSoft of Argentina (B)
Proactive Decision Making
Frito-Lay Inc.: Strategic Transition (A) (Updated)
India (B)
Rhone-Poulenc Rorer Inc.
Sees Candies: Japanese Market Entry (A)
Procter and Gamble: Cost of Capital
The Three Faces of Bounded Reliability: Alfred Chandler and the Micro-Foundations of Management Theory
Women’s Community House and Mine101: Is Social Enterprise Worth It?
